Host Genetics and Resistance to HIV-1 Infection

Models of Protection Against HIV/SIV

Volumn , Issue , 2012, Pages 169-209

  Luo, Ma ^a,b   McLaren, Paul J ^c   Plummer, Francis A ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882893186     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-387715-4.00006-X     Document Type: Chapter

References (267)

1. Fowke K.R., Nagelkerke N.J., Kimani J., Simonsen J.N., Anzala A.O., Bwayo J.J., et al. Resistance to HIV-1 infection among persistently seronegative prostitutes in Nairobi, Kenya. Lancet 1996, 348:1347-1351.
2. Plummer F.A., Ball T.B., Kimani J., Fowke K.R. Resistance to HIV-1 infection among highly exposed sex workers in Nairobi: what mediates protection and why does it develop?. Immunol Lett 1999, 66:27-34.
3. Rowland-Jones S., Sutton J., Ariyoshi K., Dong T., Gotch F., McAdam S., et al. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat Med 1995, 1:59-64.
4. Trachtenberg E.A., Erlich H.A. A review of the role of the human leukocyte antigen (HLA) system as a host immunogenetic factor influencing HIV transmission and progression to AIDS. HIV Molecular Immunology 2001, Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM. B.T. Korber, C. Brander, B.F. Haynes, R. Koup, C. Kuiken, J.P. Moore (Eds.).
5. Pereyra F., Addo M.M., Kaufmann D.E., Liu Y., Miura T., Rathod A., et al. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis 2008, 197:563-571.
6. Koning F.A., Jansen C.A., Dekker J., Kaslow R.A., Dukers N., Van Baarle D., et al. Correlates of resistance to HIV-1 infection in homosexual men with high-risk sexual behaviour. AIDS 2004, 18:1117-1126.
7. Liu R., Paxton W.A., Choe S., Ceradini D., Martin S.R., Horuk R., et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996, 86:366-377.
8. Paxton W.A., Martin S.R., Tse D., O'Brien T.R., Skurnick J., VanDevanter N.L., et al. Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure. Nat Med 1996, 2:412-417.
9. Liu H., Hwangbo Y., Holte S., Lee J., Wang C., Kaupp N., et al. Analysis of genetic polymorphisms in CCR5, CCR2, stromal cell-derived factor-1, RANTES, and dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin in seronegative individuals repeatedly exposed to HIV-1. J Infect Dis 2004, 190:1055-1058.
10. Ball T.B., Ji H., Kimani J., McLaren P., Marlin C., Hill A.V., et al. Polymorphisms in IRF-1 associated with resistance to HIV-1 infection in highly exposed uninfected Kenyan sex workers. AIDS 2007, 21:1091-1101.
11. Balotta C., Bagnarelli P., Violin M., Ridolfo A.L., Zhou D., Berlusconi A., et al. Homozygous delta 32 deletion of the CCR-5 chemokine receptor gene in an HIV-1-infected patient. AIDS 1997, 11:F67-F71.
12. Becker Y. The molecular mechanism of human resistance to HIV-1 infection in persistently infected individuals-a review, hypothesis and implications. Virus Genes 2005, 31:113-119.
13. Bhattacharya T., Stanton J., Kim E.Y., Kunstman K.J., Phair J.P., Jacobson L.P., et al. CCL3L1 and HIV/AIDS susceptibility. Nat Med 2009, 15:1110-1112.
14. Bienzle D., MacDonald K.S., Smaill F.M., Kovacs C., Baqi M., Courssaris B., et al. Factors contributing to the lack of human immunodeficiency virus type 1 (HIV-1) transmission in HIV-1-discordant partners. J Infect Dis 2000, 182:123-132.
15. Biti R., Ffrench R., Young J., Bennetts B., Stewart G., Liang T. HIV-1 infection in an individual homozygous for the CCR5 deletion allele. Nat Med 1997, 3:1240-1243.
16. Broliden K., Hinkula J., Devito C., Kiama P., Kimani J., Trabbatoni D., et al. Functional HIV-1 specific IgA antibodies in HIV-1 exposed, persistently IgG seronegative female sex workers. Immunol Lett 2001, 79:29-36.
17. Carrington M., Dean M., Martin M.P., O'Brien S.J. Genetics of HIV-1 infection: Chemokine receptor CCR5 polymorphism and its consequences. Hum Mol Genet 1999, 8:1939-1945.
18. Devito C., Broliden K., Kaul R., Svensson L., Johansen K., Kiama P., et al. Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells. J Immunol 2000, 165:5170-5176.
19. Kulkarni P.S., Butera S.T., Duerr A.C. Resistance to HIV-1 infection: Lessons learned from studies of highly exposed persistently seronegative (HEPS) individuals. AIDS Rev 2003, 5:87-103.
20. Rowland-Jones S.L., Pinheiro S., Kaul R., Hansasuta P., Gillespie G., Dong T., et al. How important is the "quality" of the cytotoxic T lymphocyte (CTL) response in protection against HIV infection?. Immunol Lett 2001, 79:15-20.
21. Tang J., Shelton B., Makhatadze N.J., Zhang Y., Schaen M., Louie L.G., et al. Distribution of chemokine receptor CCR2 and CCR5 genotypes and their relative contribution to human immunodeficiency virus type 1 (HIV-1) seroconversion, early HIV-1 RNA concentration in plasma, and later disease progression. J Virol 2002, 76:662-672.
22. Yang C., Li M., Limpakarnjanarat K., Young N.L., Hodge T., Butera S.T., et al. Polymorphisms in the CCR5 coding and noncoding regions among HIV type 1-exposed, persistently seronegative female sex-workers from Thailand. AIDS Res Hum Retroviruses 2003, 19:661-665.
23. Castelli E.C., Mendes-Junior C.T., Donadi E.A. HLA-G alleles and HLA-G 14 bp polymorphisms in a Brazilian population. Tissue Antigens 2007, 70:62-68.
24. Castelli EC, Mendes-Junior CT, Deghaide NH, de Albuquerque RS, Muniz YC, Simoes RT, et al. The genetic structure of 3'untranslated region of the HLA-G gene: Polymorphisms and haplotypes. Genes Immun 11:134-41.
25. Chen X.Y., Yan W.H., Lin A., Xu H.H., Zhang J.G., Wang X.X. The 14 bp deletion polymorphisms in HLA-G gene play an important role in the expression of soluble HLA-G in plasma. Tissue Antigens 2008, 72:335-341.
26. Colobran R., Adreani P., Ashhab Y., Llano A., Este J.A., Dominguez O., et al. Multiple products derived from two CCL4 loci: High incidence of a new polymorphism in HIV+ patients. J Immunol 2005, 174:5664-5665.
27. Duggal P., An P., Beaty T.H., Strathdee S.A., Farzadegan H., Markham R.B., et al. Genetic influence of CXCR6 chemokine receptor alleles on PCP-mediated AIDS progression among African Americans. Genes Immun 2003, 4:245-250.
28. Fabris A., Catamo E., Segat L., Morgutti M., Arraes L.C., de Lima-Filho J.L., et al. Association between HLA-G 3'UTR 14-bp polymorphism and HIV vertical transmission in Brazilian children. AIDS 2009, 23:177-182.
29. Fellay J., Ge D., Shianna K.V., Colombo S., Ledergerber B., Cirulli E.T., et al. Common genetic variation and the control of HIV-1 in humans. PLoS Genet 2009, 5:e1000791.
30. Fellay J., Shianna K.V., Ge D., Colombo S., Ledergerber B., Weale M., et al. A whole-genome association study of major determinants for host control of HIV-1. Science 2007, 317:944-947.
31. Geczy A.F., Kuipers H., Coolen M., Ashton L.J., Kennedy C., Ng G., et al. HLA and other host factors in transfusion-acquired HIV-1 infection. Hum Immunol 2000, 61:172-176.
32. Goldschmidt V., Bleiber G., May M., Martinez R., Ortiz M., Telenti A. Role of common human TRIM5alpha variants in HIV-1 disease progression. Retrovirology 2006, 3:54.
33. Gonzalez E., Dhanda R., Bamshad M., Mummidi S., Geevarghese R., Catano G., et al. Global survey of genetic variation in CCR5, RANTES, and MIP-1alpha: impact on the epidemiology of the HIV-1 pandemic. Proc Natl Acad Sci USA 2001, 98:5199-5204.
34. Gonzalez E., Rovin B.H., Sen L., Cooke G., Dhanda R., Mummidi S., et al. HIV-1 infection and AIDS dementia are influenced by a mutant MCP-1 allele linked to increased monocyte infiltration of tissues and MCP-1 levels. Proc Natl Acad Sci USA 2002, 99:13795-13800.
35. Gonzalez E., Kulkarni H., Bolivar H., Mangano A., Sanchez R., Catano G., et al. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science 2005, 307:1434-1440.
36. Gonzalez S., Tirado G., Revuelta G., Yamamura Y., Lu Y., Nerurkar V.R., et al. CCR5 chemokine receptor genotype frequencies among Puerto Rican HIV-1-seropositive individuals. Bol Asoc Med P R 1998, 90:12-15.
37. Haddad R., Ciliao Alves D.C., Rocha-Junior M.C., Azevedo R., do Socorro Pombo-de-Oliveira M., Takayanagui O.M., et al. HLA-G 14-bp insertion/deletion polymorphism is a risk factor for HTLV-1 infection. AIDS Res Hum Retroviruses 2011, 23:283-288.
38. Harrison G.A., Humphrey K.E., Jakobsen I.B., Cooper D.W. A 14 bp deletion polymorphism in the HLA-G gene. Hum Mol Genet 1993, 2:2200.
39. Ji H., Ball T.B., Kimani J., Plummer F.A. Novel interferon regulatory factor-1 polymorphisms in a Kenyan population revealed by complete gene sequencing. J Hum Genet 2004, 49:528-535.
40. Ji H., Ball T.B., Liang B.B., Kimani J., Plummer F.A. Human interferon regulatory factor-1 gene and its promoter sequences revealed by population-based complete gene sequencing. DNA Seq 2008, 19:326-331.
41. Liao H.X., Montefiori D.C., Patel D.D., Lee D.M., Scott W.K., Pericak-Vance M., et al. Linkage of the CCR5 delta 32 mutation with a functional polymorphism of CD45RA. J Immunol 2000, 165:148-157.
42. Libert F., Cochaux P., Beckman G., Samson M., Aksenova M., Cao A., et al. The deltaCCR5 mutation conferring protection against HIV-1 in Caucasian populations has a single and recent origin in Northeastern Europe. Hum Mol Genet 1998, 7:399-406.
43. Lin A., Yan W.H., Xu H.H., Tang L.J., Chen X.F., Zhu M., et al. 14 bp deletion polymorphism in the HLA-G gene is a risk factor for idiopathic dilated cardiomyopathy in a Chinese Han population. Tissue Antigens 2007, 70:427-431.
44. Martin M.P., Carrington M., Dean M., O'Brien S.J., Sheppard H.W., Wegner S.A., et al. CXCR4 polymorphisms and HIV-1 pathogenesis. J Acquir Immune Defic Syndr Hum Retrovirol 1998, 19:430.
45. Martin M.P., Lederman M.M., Hutcheson H.B., Goedert J.J., Nelson G.W., van Kooyk Y., et al. Association of DC-SIGN promoter polymorphism with increased risk for parenteral, but not mucosal, acquisition of human immunodeficiency virus type 1 infection. J Virol 2004, 78:14053-14056.
46. Matt C., Roger M. Genetic determinants of pediatric HIV-1 infection: Vertical transmission and disease progression among children. Mol Med 2001, 7:583-589.
47. McDermott D.H., Colla J.S., Kleeberger C.A., Plankey M., Rosenberg P.S., Smith E.D., et al. Genetic polymorphism in CX3CR1 and risk of HIV disease. Science 2000, 290:2031.
48. McDermott D.H., Zimmerman P.A., Guignard F., Kleeberger C.A., Leitman S.F., Murphy P.M. CCR5 promoter polymorphism and HIV-1 disease progression. Multicenter AIDS Cohort Study (MACS). Lancet 1998, 352:866-870.
49. McDermott D.H., Beecroft M.J., Kleeberger C.A., Al-Sharif F.M., Ollier W.E., Zimmerman P.A., et al. Chemokine RANTES promoter polymorphism affects risk of both HIV infection and disease progression in the Multicenter AIDS Cohort Study. AIDS 2000, 14:2671-2678.
50. Pelak K, Goldstein DB, Walley NM, Fellay J, Ge D, Shianna KV, et al. Host determinants of HIV-1 control in African Americans. J Infect Dis 201:1141-9.
51. Petersen D.C., GlashoffR.H., Shrestha S., Bergeron J., Laten A., Gold B., et al. Risk for HIV-1 infection associated with a common CXCL12 (SDF1) polymorphism and CXCR4 variation in an African population. J Acquir Immune Defic Syndr 2005, 40:521-526.
52. Price H, Lacap P, TuffJ, Wachihi C, Kimani J, Ball TB, et al. A TRIM5alpha exon 2 polymorphism is associated with protection from HIV-1 infection in the Pumwani Sex Worker cohort. AIDS 24:1813-21.
53. study. AIDS Alert 2002, 17:23-24. One copy of mutation may help resistance, 14.
54. An P., Martin M.P., Nelson G.W., Carrington M., Smith M.W., Gong K., et al. Influence of CCR5 promoter haplotypes on AIDS progression in African-Americans. AIDS 2000, 14:2117-2122.
55. Arenzana-Seisdedos F., Virelizier J.L., Rousset D., Clark-Lewis I., Loetscher P., Moser B., et al. HIV blocked by chemokine antagonist. Nature 1996, 383:400.
56. Blanpain C., Libert F., Vassart G., Parmentier M. CCR5 and HIV infection. Receptors Channels 2002, 8:19-31.
57. Chalmet K., Van Wanzeele F., Demecheleer E., Dauwe K., Pelgrom J., Van Der Gucht B., et al. Impact of delta 32-CCR5 heterozygosity on HIV-1 genetic evolution and variability-a study of 4 individuals infected with closely related HIV-1 strains. Virology 2008, 379:213-222.
58. Bratt G., Sandstrom E., Albert J., Samson M., Wahren B. The influence of MT-2 tropism on the prognostic implications of the delta32 deletion in the CCR-5 gene. AIDS 1997, 11:1415-1419.
59. Diaz F.J., Vega J.A., Patino P.J., Bedoya G., Nagles J., Villegas C., et al. Frequency of CCR5 delta-32 mutation in human immunodeficiency virus (HIV)-seropositive and HIV-exposed seronegative individuals and in general population of Medellin, Colombia. Mem Inst Oswaldo Cruz 2000, 95:237-242.
60. Gonzalez E., Bamshad M., Sato N., Mummidi S., Dhanda R., Catano G., et al. Race-specific HIV-1 disease-modifying effects associated with CCR5 haplotypes. Proc Natl Acad Sci USA 1999, 96:12004-12009.
61. Huang Y., Paxton W.A., Wolinsky S.M., Neumann A.U., Zhang L., He T., et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 1996, 2:1240-1243.
62. Hummel S., Schmidt D., Kremeyer B., Herrmann B., Oppermann M. Detection of the CCR5-delta32 HIV resistance gene in Bronze Age skeletons. Genes Immun 2005, 6:371-374.
63. Kokkotou E., Philippon V., Gueye-Ndiaye A., Mboup S., Wang W.K., Essex M., et al. Role of the CCR5 delta 32 allele in resistance to HIV-1 infection in West Africa. J Hum Virol 1998, 1:469-474.
64. Hedrick P.W., Verrelli B.C. "Ground truth" for selection on CCR5-delta32. Trends Genet 2006, 22:293-296.
65. Speelmon E.C., Livingston-RosanoffD., Li S.S., Vu Q., Bui J., Geraghty D.E., et al. Genetic association of the antiviral restriction factor TRIM5alpha with human immunodeficiency virus type 1 infection. J Virol 2006, 80:2463-2471.
66. Diaz-Griffero F., Perron M., McGee-Estrada K., Hanna R., Maillard P.V., Trono D., et al. A human TRIM5alpha B30.2/SPRY domain mutant gains the ability to restrict and prematurely uncoat B-tropic murine leukemia virus. Virology 2008, 378:233-242.
67. Takeuchi H., Matano T. Host factors involved in resistance to retroviral infection. Microbiol Immunol 2008, 52:318-325.
68. Su RC, Sivro A, Kimani J, Jaoko W, Plummer FA, Ball TB. Epigenetic control of IRF1 responses in HIV-exposed seronegative versus HIV-susceptible individuals. Blood 117:2649-57.
69. Hardie R.A., Knight E., Bruneau B., Semeniuk C., Gill K., Nagelkerke N., et al. A common human leucocyte antigen-DP genotype is associated with resistance to HIV-1 infection in Kenyan sex workers. AIDS 2008, 22:2038-2042.
70. Hardie R.A., Luo M., Bruneau B., Knight E., Nagelkerke N.J., Kimani J., et al. Human leukocyte antigen-DQ alleles and haplotypes and their associations with resistance and susceptibility to HIV-1 infection. AIDS 2008, 22:807-816.
71. Lacap P.A., Huntington J.D., Luo M., Nagelkerke N.J., Bielawny T., Kimani J., et al. Associations of human leukocyte antigen DRB with resistance or susceptibility to HIV-1 infection in the Pumwani Sex Worker cohort. AIDS 2008, 22:1029-1038.
72. MacDonald K.S., Fowke K.R., Kimani J., Dunand V.A., Nagelkerke N.J., Ball T.B., et al. Influence of HLA supertypes on susceptibility and resistance to human immunodeficiency virus type 1 infection. J Infect Dis 2000, 181:1581-1589.
73. Magierowska M., Theodorou I., Debre P., Sanson F., Autran B., Riviere Y., et al. Combined genotypes of CCR5, CCR2, SDF1, and HLA genes can predict the long-term nonprogressor status in human immunodeficiency virus-1-infected individuals. Blood 1999, 93:936-941.
74. Kreiss J.K., Kiviat N.B., Plummer F.A., Roberts P.L., Waiyaki P., Ngugi E., et al. Human immunodeficiency virus, human papillomavirus, and cervical intraepithelial neoplasia in Nairobi prostitutes. Sex Transm Dis 1992, 19:54-59.
75. Kreiss J.K., Koech D., Plummer F.A., Holmes K.K., Lightfoote M., Piot P., et al. AIDS virus infection in Nairobi prostitutes. Spread of the epidemic to East Africa. N Engl J Med 1986, 314:414-418.
76. Ndinya-achola J.O., Plummer F.A., Ronald A.R., Piot P. Acquired immunodeficiency syndrome: Epidemiology in Africa and its implications for health services. Afr J Sex Transmi Dis 1986, 2:77-80.
77. Piot P., Colebunders R., Laga M., Ndinya-Achola J.O., van der Groen G., Plummer F.A. AIDS in Africa: A public health priority. J Virol Methods 1987, 17:1-10.
78. Piot P., Kreiss J.K., Ndinya-Achola J.O., Ngugi E.N., Simonsen J.N., Cameron D.W., et al. Heterosexual transmission of HIV. AIDS 1987, 1:199-206.
79. Piot P., Plummer F.A., Mhalu F.S., Lamboray J.L., Chin J., Mann J.M. AIDS: An international perspective. Science 1988, 239:573-579.
80. Piot P., Plummer F.A., Rey M.A., Ngugi E.N., Rouzioux C., Ndinya-Achola J.O., et al. Retrospective seroepidemiology of AIDS virus infection in Nairobi populations. J Infect Dis 1987, 155:1108-1112.
81. Nagelkerke N.J., Plummer F.A., Holton D., Anzala A.O., Manji F., Ngugi E.N., et al. Transition dynamics of HIV disease in a cohort of African prostitutes: A Markov model approach. AIDS 1990, 4:743-747.
82. Ngugi E.N., Plummer F.A., Simonsen J.N., Cameron D.W., Bosire M., Waiyaki P., et al. Prevention of transmission of human immunodeficiency virus in Africa: Effectiveness of condom promotion and health education among prostitutes. Lancet 1988, 2:887-890.
83. Ngugi E.N., Plummer F.A. Health outreach and control of HIV infection in Kenya. J Acquir Immune Defic Syndr 1988, 1:566-570.
84. Plummer F.A., Ndinya-Achola J.O. Sexually transmitted diseases and HIV-1: Interactions in transmission and role in control programs. East Afr Med J 1990, 67:457-460.
85. Ronald A.R., Ndinya-Achola J.O., Plummer F.A., Simonsen J.N., Cameron D.W., Ngugi E.N., et al. A review of HIV-1 in Africa. Bull NY Acad Med 1988, 64:480-490.
86. Simonsen J.N., Cameron D.W., Gakinya M.N., Ndinya-Achola J.O., D'Costa L.J., Karasira P., et al. Human immunodeficiency virus infection among men with sexually transmitted diseases. Experience from a center in Africa. N Engl J Med 1988, 319:274-278.
87. UNAIDS. http://www.unaids.org.
88. Tersmette M., van Dongen J.J., Clapham P.R., de Goede R.E., Wolvers-Tettero I.L., Geurts van Kessel A., et al. Human immunodeficiency virus infection studied in CD4-expressing human-murine T-cell hybrids. Virology 1989, 168:267-273.
89. Weiner D.B., Huebner K., Williams W.V., Greene M.I. Human genes other than CD4 facilitate HIV-1 infection of murine cells. Pathobiology 1991, 59:361-371.
90. Cocchi F., DeVico A.L., Garzino-Demo A., Arya S.K., Gallo R.C., Lusso P. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995, 270:1811-1815.
91. Alkhatib G., Combadiere C., Broder C.C., Feng Y., Kennedy P.E., Murphy P.M., et al. CC CKR5: A RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996, 272:1955-1958.
92. Bleul C.C., Farzan M., Choe H., Parolin C., Clark-Lewis I., Sodroski J., et al. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 1996, 382:829-833.
93. Choe H., Farzan M., Sun Y., Sullivan N., Rollins B., Ponath P.D., et al. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996, 85:1135-1148.
94. Deng H., Liu R., Ellmeier W., Choe S., Unutmaz D., Burkhart M., et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996, 381:661-666.
95. Dragic T., Litwin V., Allaway G.P., Martin S.R., Huang Y., Nagashima K.A., et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996, 381:667-673.
96. Feng Y., Broder C.C., Kennedy P.E., Berger E.A. HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996, 272:827-837.
97. Dean M., Carrington M., Winkler C., Huttley G.A., Smith M.W., Allikmets R., et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996, 273:1856-1862.
98. Samson M., Libert F., Doranz B.J., Rucker J., Liesnard C., Farber C.M., et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996, 382:722-725.
99. O'Brien S.J., Dean M. In search of AIDS-resistance genes. Sci Am 1997, 277:44-51.
100. Theodorou I., Meyer L., Magierowska M., Katlama C., Rouzioux C. HIV-1 infection in an individual homozygous for CCR5 delta 32. Seroco Study Group. Lancet 1997, 349:1219-1220.
101. O'Brien S.J., Nelson G.W. Human genes that limit AIDS. Nat Genet 2004, 36:565-574.
102. Stephens J.C., Reich D.E., Goldstein D.B., Shin H.D., Smith M.W., Carrington M., et al. Dating the origin of the CCR5-delta32 AIDS-resistance allele by the coalescence of haplotypes. Am J Hum Genet 1998, 62:1507-1515.
103. Sabeti P.C., Walsh E., Schaffner S.F., Varilly P., Fry B., Hutcheson H.B., et al. The case for selection at CCR5-delta32. PLoS Biol 2005, 3:e387.
104. Hutter G., Nowak D., Mossner M., Ganepola S., Mussig A., Allers K., et al. Long-term control of HIV by CCR5 delta32/delta32 stem-cell transplantation. N Engl J Med 2009, 360:692-698.
105. Carrington M., Kissner T., Gerrard B., Ivanov S., O'Brien S.J., Dean M. Novel alleles of the chemokine-receptor gene CCR5. Am J Hum Genet 1997, 61:1261-1267.
106. Quillent C., Oberlin E., Braun J., Rousset D., Gonzalez-Canali G., Metais P., et al. HIV-1-resistance phenotype conferred by combination of two separate inherited mutations of CCR5 gene. Lancet 1998, 351:14-18.
107. Mangano A., Gonzalez E., Dhanda R., Catano G., Bamshad M., Bock A., et al. Concordance between the CC chemokine receptor 5 genetic determinants that alter risks of transmission and disease progression in children exposed perinatally to human immunodeficiency virus. J Infect Dis 2001, 183:1574-1585.
108. Capoulade-Metay C., Ma L., Truong L.X., Dudoit Y., Versmisse P., Nguyen N.V., et al. New CCR5 variants associated with reduced HIV coreceptor function in southeast Asia. AIDS 2004, 18:2243-2252.
109. Ma L., Dudoit Y., Tran T., Xing H., Chen J., Pancino G., et al. Biochemical and HIV-1 coreceptor properties of K26R, a new CCR5 Variant in China's Sichuan population. J Acquir Immune Defic Syndr 2005, 39:38-43.
110. Saez-Cirion A., Versmisse P., Truong L.X., Chakrabarti L.A., Carpentier W., Barre-Sinoussi F., et al. Persistent resistance to HIV-1 infection in CD4 T cells from exposed uninfected Vietnamese individuals is mediated by entry and post-entry blocks. Retrovirology 2006, 3:81.
111. MacDonald K.S., Embree J., Njenga S., Nagelkerke N.J., Ngatia I., Mohammed Z., et al. Mother-child class I HLA concordance increases perinatal human immunodeficiency virus type 1 transmission. J Infect Dis 1998, 177:551-556.
112. Mackelprang R.D., John-Stewart G., Carrington M., Richardson B., Rowland-Jones S., Gao X., et al. Maternal HLA homozygosity and mother-child HLA concordance increase the risk of vertical transmission of HIV-1. J Infect Dis 2008, 197:1156-1161.
113. Polycarpou A., Ntais C., Korber B.T., Elrich H.A., Winchester R., Krogstad P., et al. Association between maternal and infant class I and II HLA alleles and of their concordance with the risk of perinatal HIV type 1 transmission. AIDS Res Hum Retroviruses 2002, 18:741-746.
114. Thobakgale C.F., Prendergast A., Crawford H., Mkhwanazi N., Ramduth D., Reddy S., et al. Impact of HLA in mother and child on disease progression of pediatric human immunodeficiency virus type 1 infection. J Virol 2009, 83:10234-10244.
115. Dorak M.T., Tang J., Penman-Aguilar A., Westfall A.O., Zulu I., Lobashevsky E.S., et al. Transmission of HIV-1 and HLA-B allele-sharing within serodiscordant heterosexual Zambian couples. Lancet 2004, 363:2137-2139.
116. Lockett S.F., Robertson J.R., Brettle R.P., Yap P.L., Middleton D., Leigh Brown A.J. Mismatched human leukocyte antigen alleles protect against heterosexual HIV transmission. J Acquir Immune Defic Syndr 2001, 27:277-280.
117. Liu C., Carrington M., Kaslow R.A., Gao X., Rinaldo C.R., Jacobson L.P., et al. Association of polymorphisms in human leukocyte antigen class I and transporter associated with antigen processing genes with resistance to human immunodeficiency virus type 1 infection. J Infect Dis 2003, 187:1404-1410.
118. Rohowsky-Kochan C., Skurnick J., Molinaro D., Louria D. HLA antigens associated with susceptibility/resistance to HIV-1 infection. Hum Immunol 1998, 59:802-815.
119. MacDonald K.S., Embree J.E., Nagelkerke N.J., Castillo J., Ramhadin S., Njenga S., et al. The HLA A2/6802 supertype is associated with reduced risk of perinatal human immunodeficiency virus type 1 transmission. J Infect Dis 2001, 183:503-506.
120. Fabio G., Scorza R., Lazzarin A., Marchini M., Zarantonello M., D'Arminio A., et al. HLA-associated susceptibility to HIV-1 infection. Clin Exp Immunol 1992, 87:20-23.
121. Sriwanthana B., Hodge T., Mastro T.D., Dezzutti C.S., Bond K., Stephens H.A., et al. HIV-specific cytotoxic T lymphocytes, HLA-A11, and chemokine-related factors may act synergistically to determine HIV resistance in CCR5 delta32-negative female sex workers in Chiang Rai, northern Thailand. AIDS Res Hum Retroviruses 2001, 17:719-734.
122. Mackelprang RD, Carrington M, John-Stewart G, Lohman-Payne B, Richardson BA, Wamalwa D, et al. Maternal human leukocyte antigen A-2301 is associated with increased mother-to-child HIV-1 transmission. J Infect Dis 202:1273-7.
123. Winchester R., Chen Y., Rose S., Selby J., Borkowsky W. Major histocompatibility complex class II DR alleles DRB1-1501 and those encoding HLA-DR13 are preferentially associated with a diminution in maternally transmitted human immunodeficiency virus 1 infection in different ethnic groups: Determination by an automated sequence-based typing method. Proc Natl Acad Sci USA 1995, 92:12374-12378.
124. Winchester R., Pitt J., Charurat M., Magder L.S., Goring H.H., Landay A., et al. Mother-to-child transmission of HIV-1: Strong association with certain maternal HLA-B alleles independent of viral load implicates innate immune mechanisms. J Acquir Immune Defic Syndr 2004, 36:659-670.
125. Martin M.P., Gao X., Lee J.H., Nelson G.W., Detels R., Goedert J.J., et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet 2002, 31:429-434.
126. Martin M.P., Nelson G., Lee J.H., Pellett F., Gao X., Wade J., et al. Cutting edge: Susceptibility to psoriatic arthritis: Influence of activating killer Ig-like receptor genes in the absence of specific HLA-C alleles. J Immunol 2002, 169:2818-2822.
127. Martin M.P., Qi Y., Gao X., Yamada E., Martin J.N., Pereyra F., et al. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet 2007, 39:733-740.
128. Jennes W., Verheyden S., Demanet C., Adje-Toure C.A., Vuylsteke B., Nkengasong J.N., et al. Cutting edge: Resistance to HIV-1 infection among African female sex workers is associated with inhibitory KIR in the absence of their HLA ligands. J Immunol 2006, 177:6588-6592.
129. Boulet S., Kleyman M., Kim J.Y., Kamya P., SharafiS., Simic N., et al. A combined genotype of KIR3DL1 high expressing alleles and HLA-B-57 is associated with a reduced risk of HIV infection. AIDS 2008, 22:1487-1491.
130. Boulet S., SharafiS., Simic N., Bruneau J., Routy J.P., Tsoukas C.M., et al. Increased proportion of KIR3DS1 homozygotes in HIV-exposed uninfected individuals. AIDS 2008, 22:595-599.
131. Urban T.J., Weintrob A.C., Fellay J., Colombo S., Shianna K.V., Gumbs C., et al. CCL3L1 and HIV/AIDS susceptibility. Nat Med 2009, 15:1112-1115.
132. Field S.F., Howson J.M., Maier L.M., Walker S., Walker N.M., Smyth D.J., et al. Experimental aspects of copy number variant assays at CCL3L1. Nat Med 2009, 15:1115-1117.
133. Gardner L., Patterson A.M., Ashton B.A., Stone M.A., Middleton J. The human Duffy antigen binds selected inflammatory but not homeostatic chemokines. Biochem Biophys Res Commun 2004, 321:306-312.
134. Lachgar A., Jaureguiberry G., Le Buenac H., Bizzini B., Zagury J.F., Rappaport J., et al. Binding of HIV-1 to RBCs involves the Duffy antigen receptors for chemokines (DARC). Biomed Pharmacother 1998, 52:436-439.
135. Horuk R., Chitnis C.E., Darbonne W.C., Colby T.J., Rybicki A., Hadley T.J., et al. A receptor for the malarial parasite Plasmodium vivax: The erythrocyte chemokine receptor. Science 1993, 261:1182-1184.
136. He W., Neil S., Kulkarni H., Wright E., Agan B.K., Marconi V.C., et al. Duffy antigen receptor for chemokines mediates trans-infection of HIV-1 from red blood cells to target cells and affects HIV-AIDS susceptibility. Cell Host Microbe 2008, 4:52-62.
137. Horne K.C., Li X., Jacobson L.P., Palella F., Jamieson B.D., Margolick J.B., et al. Duffy antigen polymorphisms do not alter progression of HIV in African Americans in the MACS cohort. Cell Host Microbe 2009, 5:415-417.
138. Winkler C.A., An P., Johnson R., Nelson G.W., Kirk G. Expression of Duffy antigen receptor for chemokines (DARC) has no effect on HIV-1 acquisition or progression to AIDS in African Americans. Cell Host Microbe 2009, 5:411-413.
139. Walley N.M., Julg B., Dickson S.P., Fellay J., Ge D., Walker B.D., et al. The Duffy antigen receptor for chemokines null promoter variant does not influence HIV-1 acquisition or disease progression. Cell Host Microbe 2009, 5:408-410.
140. Geijtenbeek T.B., van Kooyk Y. DC-SIGN: A novel HIV receptor on DCs that mediates HIV-1 transmission. Curr Top Microbiol Immunol 2003, 276:31-54.
141. Bashirova A.A., Geijtenbeek T.B., van Duijnhoven G.C., van Vliet S.J., Eilering J.B., Martin M.P., et al. A dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin (DC-SIGN)-related protein is highly expressed on human liver sinusoidal endothelial cells and promotes HIV-1 infection. J Exp Med 2001, 193:671-678.
142. Mitchell D.A., Fadden A.J., Drickamer K. A novel mechanism of carbohydrate recognition by the C-type lectins DC-SIGN and DC-SIGNR. Subunit organization and binding to multivalent ligands. J Biol Chem 2001, 276:28939-28945.
143. Zhang J., Zhang X., Fu J., Bi Z., Arheart K.L., Barreiro L.B., et al. Protective role of DC-SIGN (CD209) neck-region alleles with <5 repeat units in HIV-1 transmission. J Infect Dis 2008, 198:68-71.
144. Lichterfeld M., Nischalke H.D., van Lunzen J., Sohne J., Schmeisser N., Woitas R., et al. The tandem-repeat polymorphism of the DC-SIGNR gene does not affect the susceptibility to HIV infection and the progression to AIDS. Clin Immunol 2003, 107:55-59.
145. Liu H., Carrington M., Wang C., Holte S., Lee J., Greene B., et al. Repeat-region polymorphisms in the gene for the dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin-related molecule: Effects on HIV-1 susceptibility. J Infect Dis 2006, 193:698-702.
146. Wichukchinda N., Kitamura Y., Rojanawiwat A., Nakayama E.E., Song H., Pathipvanich P., et al. The polymorphisms in DC-SIGNR affect susceptibility to HIV type 1 infection. AIDS Res Hum Retroviruses 2007, 23:686-692.
147. Rathore A., Chatterjee A., Sivarama P., Yamamoto N., Dhole T.N. Role of homozygous DC-SIGNR 5/5 tandem repeat polymorphism in HIV-1 exposed seronegative North Indian individuals. J Clin Immunol 2008, 28:50-57.
148. Vallinoto A.C., Menezes-Costa M.R., Alves A.E., Machado L.F., de Azevedo V.N., Souza L.L., et al. Mannose-binding lectin gene polymorphism and its impact on human immunodeficiency virus 1 infection. Mol Immunol 2006, 43:1358-1362.
149. Pastinen T., Liitsola K., Niini P., Salminen M., Syvanen A.C. Contribution of the CCR5 and MBL genes to susceptibility to HIV type 1 infection in the Finnish population. AIDS Res Hum Retroviruses 1998, 14:695-698.
150. Garred P., Madsen H.O., Balslev U., Hofmann B., Pedersen C., Gerstoft J., et al. Susceptibility to HIV infection and progression of AIDS in relation to variant alleles of mannose-binding lectin. Lancet 1997, 349:236-240.
151. Boniotto M., Braida L., Pirulli D., Arraes L., Amoroso A., Crovella S. MBL2 polymorphisms are involved in HIV-1 infection in Brazilian perinatally infected children. AIDS 2003, 17:779-780.
152. Boniotto M., Crovella S., Pirulli D., Scarlatti G., Spano A., Vatta L., et al. Polymorphisms in the MBL2 promoter correlated with risk of HIV-1 vertical transmission and AIDS progression. Genes Immun 2000, 1:346-348.
153. Catano G., Agan B.K., Kulkarni H., Telles V., Marconi V.C., Dolan M.J., et al. Independent effects of genetic variations in mannose-binding lectin influence the course of HIV disease: The advantage of heterozygosity for coding mutations. J Infect Dis 2008, 198:72-80.
154. Winkler C., Modi W., Smith M.W., Nelson G.W., Wu X., Carrington M., et al. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort
155. Wang C., Song W., Lobashevsky E., Wilson C.M., Douglas S.D., Mytilineos J., et al. Cytokine and chemokine gene polymorphisms among ethnically diverse North Americans with HIV-1 infection. J Acquir Immune Defic Syndr 2004, 35:446-454.
156. Tiensiwakul P. Stromal cell-derived factor (SDF) 1-3'A polymorphism may play a role in resistance to HIV-1 infection in seronegative high-risk Thais. Intervirology 2004, 47:87-92.
157. Reiche E.M., Ehara Watanabe M.A., Bonametti A.M., Kaminami Morimoto H., Akira Morimoto A., Wiechmann S.L., et al. The effect of stromal cell-derived factor 1 (SDF1/CXCL12) genetic polymorphism on HIV-1 disease progression. Intl J Mol Med 2006, 18:785-793.
158. Royo J.L., Ruiz A., Borrego S., Rubio A., Sanchez B., Nunez-Roldan A., et al. Fluorescence resonance energy transfer analysis of CCR-V64I and SDF1-3'a polymorphisms: Prevalence in southern Spain HIV type 1+ cohort and noninfected population. AIDS Res Hum Retroviruses 2001, 17:663-666.
159. Suresh P., Wanchu A., Sachdeva R.K., Bhatnagar A. Gene polymorphisms in CCR5, CCR2, CX3CR1, SDF-1 and RANTES in exposed but uninfected partners of HIV-1 infected individuals in North India. J Clin Immunol 2006, 26:476-484.
160. Tan XH, Zhang JY, Di CH, Hu AR, Yang L, Qu S, et al. Distribution of CCR5-delta32, CCR5m303A, CCR2-64I and SDF1-3'A in HIV-1 infected and uninfected high-risk Uighurs in Xinjiang, China. Infect Genet Evol 10:268-72.
161. Soriano A., Martinez C., Garcia F., Plana M., Palou E., Lejeune M., et al. Plasma stromal cell-derived factor (SDF)-1 levels, SDF1-3'A genotype, and expression of CXCR4 on T lymphocytes: Their impact on resistance to human immunodeficiency virus type 1 infection and its progression. J Infect Dis 2002, 186:922-931.
162. Stremlau M., Owens C.M., Perron M.J., Kiessling M., Autissier P., Sodroski J. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 2004, 427:848-853.
163. Sheehy A.M., Gaddis N.C., Choi J.D., Malim M.H. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002, 418:646-650.
164. Valcke H.S., Bernard N.F., Bruneau J., Alary M., Tsoukas C.M., Roger M. APOBEC3G genetic variants and their association with risk of HIV infection in highly exposed Caucasians. AIDS 2006, 20:1984-1986.
165. An P., Johnson R., Phair J., Kirk G.D., Yu X.F., Donfield S., et al. APOBEC3B deletion and risk of HIV-1 acquisition. J Infect Dis 2009, 200:1054-1058.
166. Javanbakht H., An P., Gold B., Petersen D.C., O'Huigin C., Nelson G.W., et al. Effects of human TRIM5alpha polymorphisms on antiretroviral function and susceptibility to human immunodeficiency virus infection. Virology 2006, 354:15-27.
167. Franke E.K., Yuan H.E., Luban J. Specific incorporation of cyclophilin A into HIV-1 virions. Nature 1994, 372:359-362.
168. Luban J., Bossolt K.L., Franke E.K., Kalpana G.V., GoffS.P. Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B. Cell 1993, 73:1067-1078.
169. An P., Wang L.H., Hutcheson-Dilks H., Nelson G., Donfield S., Goedert J.J., et al. Regulatory polymorphisms in the cyclophilin A gene, PPIA, accelerate progression to AIDS. PLoS Pathog 2007, 3:e88.
170. Cardoso C.B., Uthida-Tanaka A.M., Magalhaes R.F., Magna L.A., Kraemer M.H. Association between psoriasis vulgaris and MHC-DRB, -DQB genes as a contribution to disease diagnosis. Eur J Dermatol 2005, 15:159-163.
171. Plummer F.A., Laga M., Brunham R.C., Piot P., Ronald A.R., Bhullar V., et al. Postpartum upper genital tract infections in Nairobi, Kenya: Epidemiology, etiology, and risk factors. J Infect Dis 1987, 156:92-98.
172. Plummer F.A., Nagelkerke N.J., Moses S., Ndinya-Achola J.O., Bwayo J., Ngugi E. The importance of core groups in the epidemiology and control of HIV-1 infection. AIDS 1991, 5(Suppl 1):S169-S176.
173. Ronald A.R., Plummer F. Chancroid. A newly important sexually transmitted disease. Arch Dermatol 1989, 125:1413-1414.
174. Ronald A.R., Plummer F.A. Chancroid and Haemophilus ducreyi. Ann Intern Med 1985, 102:705-707.
175. Plummer F.A., D'Costa L.J., Nsanze H., Dylewski J., Karasira P., Ronald A.R. Epidemiology of chancroid and Haemophilus ducreyi in Nairobi, Kenya. Lancet 1983, 2:1293-1295.
176. Plummer F.A., Brunham R.C. Gonococcal recidivism, diversity, and ecology. Rev Infect Dis 1987, 9:846-850.
177. Plummer F.A., Simonsen J.N., Chubb H., Slaney L., Kimata J., Bosire M., et al. Epidemiologic evidence for the development of serovar-specific immunity after gonococcal infection. J Clin Invest 1989, 83:1472-1476.
178. Plummer F.A., Maggwa N., D'Costa L.J., Nsanze H., Karasira P., Maclean I.W., et al. Cefotaxime treatment of Haemophilus ducreyi infection in Kenya. Sex Transm Dis 1984, 11:304-307.
179. Plummer F.A., D'Costa L.J., Nsanze H., Karasira P., MacLean I.W., Piot P., et al. Clinical and microbiologic studies of genital ulcers in Kenyan women. Sex Transm Dis 1985, 12:193-197.
180. Datta P., Laga M., Plummer F.A., Ndinya-Achola J.O., Piot P., Maitha G., et al. Infection and disease after perinatal exposure to Chlamydia trachomatis in Nairobi, Kenya. J Infect Dis 1988, 158:524-528.
181. D'Costa L.J., Plummer F.A., Bowmer I., Fransen L., Piot P., Ronald A.R., et al. Prostitutes are a major reservoir of sexually transmitted diseases in Nairobi, Kenya. Sex Transm Dis 1985, 12:64-67.
182. Simonsen J.N., Plummer F.A., Ngugi E.N., Black C., Kreiss J.K., Gakinya M.N., et al. HIV infection among lower socioeconomic strata prostitutes in Nairobi. AIDS 1990, 4:139-144.
183. Miura T., Brockman M.A., Schneidewind A., Lobritz M., Pereyra F., Rathod A., et al. HLA-B57/B-5801 human immunodeficiency virus type 1 elite controllers select for rare Gag variants associated with reduced viral replication capacity and strong cytotoxic T-lymphocyte recognition. J Virol 2009, 83:2743-2755.
184. McNeil A.J., Yap P.L., Gore S.M., Brettle R.P., McColl M., Wyld R., et al. Association of HLA types A1-B8-DR3 and B27 with rapid and slow progression of HIV disease. Q J Med 1996, 89:177-185.
185. Costello C., Tang J., Rivers C., Karita E., Meizen-Derr J., Allen S., et al. HLA-B-5703 independently associated with slower HIV-1 disease progression in Rwandan women. AIDS 1999, 13:1990-1991.
186. Wang S.S., Hildesheim A., Gao X., Schiffman M., Herrero R., Bratti M.C., et al. Comprehensive analysis of human leukocyte antigen class I alleles and cervical neoplasia in 3 epidemiologic studies. J Infect Dis 2002, 186:598-605.
187. Moore C.B., John M., James I.R., Christiansen F.T., Witt C.S., Mallal S.A. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 2002, 296:1439-1443.
188. Carrington M., O'Brien S.J. The influence of HLA genotype on AIDS. Annu Rev Med 2003, 54:535-551.
189. Kawashima Y., Pfafferott K., Frater J., Matthews P., Payne R., Addo M., et al. Adaptation of HIV-1 to human leukocyte antigen class I. Nature 2009, 458:641-645.
190. Cassinotti A., Birindelli S., Clerici M., Trabattoni D., Lazzaroni M., Ardizzone S., et al. HLA and autoimmune digestive disease: A clinically oriented review for gastroenterologists. Am J Gastroenterol 2009, 104:195-217.
191. Sanz L., Gonzalez-Escribano F., de Pablo R., Nunez-Roldan A., Kreisler M., Vilches C. HLA-Cw-1602: A new susceptibility marker of Behcet's disease in southern Spain. Tissue Antigens 1998, 51:111-114.
192. Hendel H., Caillat-Zucman S., Lebuanec H., Carrington M., O'Brien S., Andrieu J.M., et al. New class I and II HLA alleles strongly associated with opposite patterns of progression to AIDS. J Immunol 1999, 162:6942-6946.
193. Ngumbela K.C., Day C.L., Mncube Z., Nair K., Ramduth D., Thobakgale C., et al. Targeting of a CD8 T cell env epitope presented by HLA-B-5802 is associated with markers of HIV disease progression and lack of selection pressure. AIDS Res Hum Retroviruses 2008, 24:72-82.
194. Jin X., Gao X., Ramanathan M., Deschenes G.R., Nelson G.W., O'Brien S.J., et al. Human immunodeficiency virus type 1 (HIV-1)-specific CD8+-T-cell responses for groups of HIV-1-infected individuals with different HLA-B-35 genotypes. J Virol 2002, 76:12603-12610.
195. Farquhar C., Rowland-Jones S., Mbori-Ngacha D., Redman M., Lohman B., Slyker J., et al. Human leukocyte antigen (HLA) B-18 and protection against mother-to-child HIV type 1 transmission. AIDS Res Hum Retroviruses 2004, 20:692-697.
196. Beyrer C., Artenstein A.W., Rugpao S., Stephens H., VanCott T.C., Robb M.L., et al. Epidemiologic and biologic characterization of a cohort of human immunodeficiency virus type 1 highly exposed, persistently seronegative female sex workers in northern Thailand. Chiang Mai HEPS Working Group. J Infect Dis 1999, 179:59-67.
197. Carrington M., Nelson G.W., Martin M.P., Kissner T., Vlahov D., Goedert J.J., et al. HLA and HIV-1: Heterozygote advantage and B-35-Cw-04 disadvantage. Science 1999, 283:1748-1752.
198. Borghans J.A., Molgaard A., de Boer R.J., Kesmir C. HLA alleles associated with slow progression to AIDS truly prefer to present HIV-1 p24. PLoS One 2007, 2:e920.
199. Emu B., Sinclair E., Hatano H., Ferre A., Shacklett B., Martin J.N., et al. HLA class I-restricted T-cell responses may contribute to the control of human immunodeficiency virus infection, but such responses are not always necessary for long-term virus control. J Virol 2008, 82:5398-5407.
200. Gao X., Nelson G.W., Karacki P., Martin M.P., Phair J., Kaslow R., et al. Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. N Engl J Med 2001, 344:1668-1675.
201. Kiepiela P., Leslie A.J., Honeyborne I., Ramduth D., Thobakgale C., Chetty S., et al. Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature 2004, 432:769-775.
202. Rousseau C.M., Daniels M.G., Carlson J.M., Kadie C., Crawford H., Prendergast A., et al. HLA class I-driven evolution of human immunodeficiency virus type 1 subtype c proteome: Immune escape and viral load. J Virol 2008, 82:6434-6446.
203. Steel C.M., Ludlam C.A., Beatson D., Peutherer J.F., Cuthbert R.J., Simmonds P., et al. HLA haplotype A1 B8 DR3 as a risk factor for HIV-related disease. Lancet 1988, 1:1185-1188.
204. Trachtenberg E., Korber B., Sollars C., Kepler T.B., Hraber P.T., Hayes E., et al. Advantage of rare HLA supertype in HIV disease progression. Nat Med 2003, 9:928-935.
205. de Sorrentino A.H., Marinic K., Motta P., Sorrentino A., Lopez R., Illiovich E. HLA class I alleles associated with susceptibility or resistance to human immunodeficiency virus type 1 infection among a population in Chaco Province, Argentina. J Infect Dis 2000, 182:1523-1526.
206. Ndung'u T., Gaseitsiwe S., Sepako E., Doualla-Bell F., Peter T., Kim S., et al. Major histocompatibility complex class II (HLA-DRB and -DQB) allele frequencies in Botswana: Association with human immunodeficiency virus type 1 infection. Clin Diagn Lab Immunol 2005, 12:1020-1028.
207. Tang J., Penman-Aguilar A., Lobashevsky E., Allen S., Kaslow R.A. HLA-DRB1 and -DQB1 alleles and haplotypes in Zambian couples and their associations with heterosexual transmission of HIV type 1. J Infect Dis 2004, 189:1696-1704.
208. Selvaraj P., Swaminathan S., Alagarasu K., Raghavan S., Narendran G., Narayanan P. Association of human leukocyte antigen-A11 with resistance and B40 and DR2 with susceptibility to HIV-1 infection in south India. J Acquir Immune Defic Syndr 2006, 43:497-499.
209. Sun J.C., Bevan M.J. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 2003, 300:339-342.
210. Sun J.C., Williams M.A., Bevan M.J. CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection. Nat Immunol 2004, 5:927-933.
211. Shedlock D.J., Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 2003, 300:337-339.
212. Shedlock D.J., Whitmire J.K., Tan J., MacDonald A.S., Ahmed R., Shen H. Role of CD4 T cell help and costimulation in CD8 T cell responses during Listeria monocytogenes infection. J Immunol 2003, 170:2053-2063.
213. Bourgeois C., Veiga-Fernandes H., Joret A.M., Rocha B., Tanchot C. CD8 lethargy in the absence of CD4 help. Eur J Immunol 2002, 32:2199-2207.
214. Bourgeois C., Tanchot C. Mini-review CD4 T cells are required for CD8 T cell memory generation. Eur J Immunol 2003, 33:3225-3231.
215. Ogg G.S., Jin X., Bonhoeffer S., Dunbar P.R., Nowak M.A., Monard S., et al. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 1998, 279:2103-2106.
216. Koup R.A., Safrit J.T., Cao Y., Andrews C.A., McLeod G., Borkowsky W., et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994, 68:4650-4655.
217. Harrer T., Harrer E., Kalams S.A., Barbosa P., Trocha A., Johnson R.P., et al. Cytotoxic T lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection. Breadth and specificity of the response and relation to in vivo viral quasispecies in a person with prolonged infection and low viral load. J Immunol 1996, 156:2616-2623.
218. Harrer T., Harrer E., Kalams S.A., Elbeik T., Staprans S.I., Feinberg M.B., et al. Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection. AIDS Res Hum Retroviruses 1996, 12:585-592.
219. Kapustin S.I., Popova T.I., Lyschov A.A., Togo A.V., Abdulkadyrov K.M., Blinov M.N. HLA-DR2 frequency increase in severe aplastic anemia patients is mainly attributed to the prevalence of DR15 subtype. Pathol Oncol Res 1997, 3:106-108.
220. Prat E., Tomaru U., Sabater L., Park D.M., Granger R., Kruse N., et al. HLA-DRB5-0101 and -DRB1-1501 expression in the multiple sclerosis-associated HLA-DR15 haplotype. J Neuroimmunol 2005, 167:108-119.
221. Kapitany A., Zilahi E., Szanto S., Szucs G., Szabo Z., Vegvari A., et al. Association of rheumatoid arthritis with HLA-DR1 and HLA-DR4 in Hungary. Ann NY Acad Sci 2005, 1051:263-270.
222. Zsilak S., Gal J., Hodinka L., Rajczy K., Balog A., Sipka S., et al. HLA-DR genotypes in familial rheumatoid arthritis: Increased frequency of protective and neutral alleles in a multicase family. J Rheumatol 2005, 32:2299-2302.
223. Debaz H., Olivo A., Vazquez Garcia M.N., de la Rosa G., Hernandez A., Lino L., et al. Relevant residues of DRbeta1 third hypervariable region contributing to the expression and to severity of rheumatoid arthritis (RA) in Mexicans. Hum Immunol 1998, 59:287-294.
224. Matsuki K., Grumet F.C., Lin X., Gelb M., Guilleminault C., Dement W.C., et al. DQ (rather than DR) gene marks susceptibility to narcolepsy. Lancet 1992, 339:1052.
225. Fogdell A., Hillert J., Sachs C., Olerup O. The multiple sclerosis- and narcolepsy-associated HLA class II haplotype includes the DRB5-0101 allele. Tissue Antigens 1995, 46:333-336.
226. Baisch J.M., Weeks T., Giles R., Hoover M., Stastny P., Capra J.D. Analysis of HLA-DQ genotypes and susceptibility in insulin-dependent diabetes mellitus. N Engl J Med 1990, 322:1836-1841.
227. Todd J.A., Bell J.I., McDevitt H.O. A molecular basis for genetic susceptibility to insulin-dependent diabetes mellitus. Trends Genet 1988, 4:129-134.
228. Yang S., Wang J.Y., Gao M., Liu H.S., Sun L.D., He P.P., et al. Association of HLA-DQA1 and DQB1 genes with vitiligo in Chinese Hans. Int J Dermatol 2005, 44:1022-1027.
229. Geng L., Wang Y., Zhai N., Lu Y.N., Song F.J., Chen H.D. Association between pemphigus vulgaris and human leukocyte antigen in Han nation of northeast China. Chin Med Sci J 2005, 20:166-170.
230. Cinek O., Kolouskova S., Snajderova M., Sumnik Z., Sedlakova P., Drevinek P., et al. HLA class II genetic association of type 1 diabetes mellitus in Czech children. Pediatr Diabetes 2001, 2:98-102.
231. Bieniasz P.D. Intrinsic immunity: A front-line defense against viral attack. Nat Immunol 2004, 5:1109-1115.
232. Yap M.W., Nisole S., Lynch C., Stoye J.P. Trim5alpha protein restricts both HIV-1 and murine leukemia virus. Proc Natl Acad Sci USA 2004, 101:10786-10791.
233. Perron M.J., Stremlau M., Song B., Ulm W., Mulligan R.C., Sodroski J. TRIM5alpha mediates the postentry block to N-tropic murine leukemia viruses in human cells. Proc Natl Acad Sci USA 2004, 101:11827-11832.
234. Lee K., KewalRamani V.N. In defense of the cell: TRIM5alpha interception of mammalian retroviruses. Proc Natl Acad Sci USA 2004, 101:10496-10497.
235. Sokolskaja E., Berthoux L., Luban J. Cyclophilin A and TRIM5alpha independently regulate human immunodeficiency virus type 1 infectivity in human cells. J Virol 2006, 80:2855-2862.
236. van Manen D., Rits M.A., Beugeling C., van Dort K., Schuitemaker H., Kootstra N.A. The effect of Trim5 polymorphisms on the clinical course of HIV-1 infection. PLoS Pathog 2008, 4:e18.
237. Nakayama E.E., Carpentier W., Costagliola D., Shioda T., Iwamoto A., Debre P., et al. Wild type and H43Y variant of human TRIM5alpha show similar anti-human immunodeficiency virus type 1 activity both in vivo and in vitro. Immunogenetics 2007, 59:511-515.
238. Stremlau M., Perron M., Lee M., Li Y., Song B., Javanbakht H., et al. Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor. Proc Natl Acad Sci USA 2006, 103:5514-5519.
239. Perez-Caballero D., Hatziioannou T., Yang A., Cowan S., Bieniasz P.D. Human tripartite motif 5alpha domains responsible for retrovirus restriction activity and specificity. J Virol 2005, 79:8969-8978.
240. Mische C.C., Javanbakht H., Song B., Diaz-Griffero F., Stremlau M., Strack B., et al. Retroviral restriction factor TRIM5alpha is a trimer. J Virol 2005, 79:14446-14450.
241. Javanbakht H., Diaz-Griffero F., Stremlau M., Si Z., Sodroski J. The contribution of RING and B-box 2 domains to retroviral restriction mediated by monkey TRIM5alpha. J Biol Chem 2005, 280:26933-26940.
242. Li X., Sodroski J. The TRIM5alpha B-box 2 domain promotes cooperative binding to the retroviral capsid by mediating higher-order self-association. J Virol 2008, 82:11495-11502.
243. Song B., Gold B., O'Huigin C., Javanbakht H., Li X., Stremlau M., et al. The B30.2(SPRY) domain of the retroviral restriction factor TRIM5alpha exhibits lineage-specific length and sequence variation in primates. J Virol 2005, 79:6111-6121.
244. Taniguchi T., Ogasawara K., Takaoka A., Tanaka N. IRF family of transcription factors as regulators of host defense. Annu Rev Immunol 2001, 19:623-655.
245. Taki S., Sato T., Ogasawara K., Fukuda T., Sato M., Hida S., et al. Multistage regulation of Th1-type immune responses by the transcription factor IRF-1. Immunity 1997, 6:673-679.
246. LohoffM., Ferrick D., Mittrucker H.W., Duncan G.S., Bischof S., RollinghoffM., et al. Interferon regulatory factor-1 is required for a T helper 1 immune response in vivo. Immunity 1997, 6:681-689.
247. Battistini A., Marsili G., Sgarbanti M., Ensoli B., Hiscott J. IRF regulation of HIV-1 long terminal repeat activity. J Interferon Cytokine Res 2002, 22:27-37.
248. Marsili G., Borsetti A., Sgarbanti M., Remoli A.L., RidolfiB., Stellacci E., et al. On the role of interferon regulatory factors in HIV-1 replication. Ann NY Acad Sci 2003, 1010:29-42.
249. Ji H, Ball TB, Ao Z, Kimani J, Yao X, Plummer FA. Reduced HIV-1 long terminal repeat transcription in subjects with protective interferon regulatory factor-1 genotype: A potential mechanism mediating resistance to infection by HIV-1. Scand J Infect Dis 42:389-94.
250. Bach M.A., Phan-Dinh-Tuy F., Bach J.F., Wallach D., Biddison W.E., Sharrow S.O., et al. Unusual phenotypes of human inducer T cells as measured by OKT4 and related monoclonal antibodies. J Immunol 1981, 127:980-982.
251. Lederman S., DeMartino J.A., Daugherty B.L., Foeldvari I., Yellin M.J., Cleary A.M., et al. A single amino acid substitution in a common African allele of the CD4 molecule ablates binding of the monoclonal antibody, OKT4. Mol Immunol 1991, 28:1171-1181.
252. Hodge T.W., Sasso D.R., McDougal J.S. Humans with OKT4-epitope deficiency have a single nucleotide base change in the CD4 gene, resulting in substitution of TRP240 for ARG240. Hum Immunol 1991, 30:99-104.
253. Maddon P.J., Littman D.R., Godfrey M., Maddon D.E., Chess L., Axel R. The isolation and nucleotide sequence of a cDNA encoding the T cell surface protein T4: A new member of the immunoglobulin gene family. Cell 1985, 42:93-104.
254. Matthias L.J., Yam P.T., Jiang X.M., VandegraaffN., Li P., Poumbourios P., et al. Disulfide exchange in domain 2 of CD4 is required for entry of HIV-1. Nat Immunol 2002, 3:727-732.
255. Fleury S., Lamarre D., Meloche S., Ryu S.E., Cantin C., Hendrickson W.A., et al. Mutational analysis of the interaction between CD4 and class II MHC: Class II antigens contact CD4 on a surface opposite the gp120-binding site. Cell 1991, 66:1037-1049.
256. Fuller T.C., Trevithick J.E., Fuller A.A., Colvin R.B., Cosimi A.B., Kung P.C. Antigenic polymorphism of the T4 differentiation antigen expressed on human T helper/inducer lymphocytes. Hum Immunol 1984, 9:89-102.
257. Oyugi J., Vouriot F.C.M., Alimonti J., Stephen Wayne S., Luo M., Land A.M., et al. A common CD4 gene variant is associated with increased risk of HIV-1 infection in Kenyan female sex workers. J Infect Dis 2009, 199:1327-1334.
258. Kitano H. Systems biology: A brief overview. Science 2002, 295:1662-1664.
259. Songok EM, Osero B, McKinnon L, Rono MK, Apidi W, Matey EJ, et al. CD26/dipeptidyl peptidase IV (CD26/DPPIV) is highly expressed in peripheral blood of HIV-1 exposed uninfected female sex workers. Virol J 7:343.
260. Burgener A., Boutilier J., Wachihi C., Kimani J., Carpenter M., Westmacott G., et al. Identification of differentially expressed proteins in the cervical mucosa of HIV-1-resistant sex workers. J Proteome Res 2008, 7:4446-4454.
261. Boonacker E., Van Noorden C.J. The multifunctional or moonlighting protein CD26/DPPIV. Eur J Cell Biol 2003, 82:53-73.
262. Gorrell M.D. Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. Clin Sci (Lond) 2005, 108:277-292.
263. Ohtsuki T., Tsuda H., Morimoto C. Good or evil: CD26 and HIV infection. J Dermatol Sci 2000, 22:152-160.
264. Ohtsuki T., Hosono O., Kobayashi H., Munakata Y., Souta A., Shioda T., et al. Negative regulation of the anti-human immunodeficiency virus and chemotactic activity of human stromal cell-derived factor 1alpha by CD26/dipeptidyl peptidase IV. FEBS Lett 1998, 431:236-240.
265. Proost P., Menten P., Struyf S., Schutyser E., De Meester I., Van Damme J. Cleavage by CD26/dipeptidyl peptidase IV converts the chemokine LD78beta into a most efficient monocyte attractant and CCR1 agonist. Blood 2000, 96:1674-1680.
266. De Meester I., Korom S., Van Damme J., Scharpe S. CD26, let it cut or cut it down. Immunol Today 1999, 20:367-375.
267. Schols D., Proost P., Struyf S., Wuyts A., De Meester I., Scharpe S., et al. CD26-processed RANTES(3-68), but not intact RANTES, has potent anti-HIV-1 activity. Antiviral Res 1998, 39:175-187.